Literature DB >> 17473062

Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis.

Stefan O Ciurea1, Delwin Merchant, Nadim Mahmud, Takefumi Ishii, Yan Zhao, Wenyang Hu, Edward Bruno, Giovanni Barosi, Mingjiang Xu, Ronald Hoffman.   

Abstract

In order to investigate the biologic processes underlying and resulting from the megakaryocytic hyperplasia that characterizes idiopathic myelofibrosis (IMF), peripheral blood CD34+ cells isolated from patients with IMF, polycythemia vera (PV), and G-CSF-mobilized healthy volunteers were cultured in the presence of stem cell factor and thrombopoietin. IMF CD34+ cells generated 24-fold greater numbers of megakaryocytes (MKs) than normal CD34+ cells. IMF MKs were also shown to have a delayed pattern of apoptosis and to overexpress the antiapoptotic protein bcl-xL. MK hyperplasia in IMF is, therefore, likely a consequence of both the increased ability of IMF progenitor cells to generate MKs and a decreased rate of MK apoptosis. Media conditioned (CM) by CD61+ cells generated in vitro from CD34+ cells were then assayed for the levels of growth factors and proteases. Higher levels of transforming growth factor-beta (TGF-beta) and active matrix metalloproteinase-9 (MMP9) were observed in media conditioned with IMF CD61+ cells than normal or PV CD61+ cells. Both normal and IMF CD61+ cells produced similar levels of VEGF. MK-derived TGF-B and MMP-9, therefore, likely contribute to the development of many pathological epiphenomena associated with IMF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473062      PMCID: PMC1924766          DOI: 10.1182/blood-2006-12-064626

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

1.  Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia.

Authors:  G Barosi; G Viarengo; A Pecci; V Rosti; G Piaggio; M Marchetti; F Frassoni
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

2.  Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis.

Authors:  F Di Raimondo; M P Azzaro; G A Palumbo; S Bagnato; F Stagno; G M Giustolisi; E Cacciola; G Sortino; P Guglielmo; R Giustolisi
Journal:  Leukemia       Date:  2001-06       Impact factor: 11.528

3.  Antiapoptotic protein Bcl-x(L) is up-regulated during megakaryocytic differentiation of CD34(+) progenitors but is absent from senescent megakaryocytes.

Authors:  C Sanz; I Benet; C Richard; B Badia; E J Andreu; F Prosper; J L Fernández-Luna
Journal:  Exp Hematol       Date:  2001-06       Impact factor: 3.084

Review 4.  Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines.

Authors:  G Barosi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

Review 5.  In vitro expansion of human megakaryocytes as a tool for studying megakaryocytic development and function.

Authors:  M Majka; M Baj-Krzyworzeka; J Kijowski; R Reca; J Ratajczak; M Z Ratajczak
Journal:  Platelets       Date:  2001-09       Impact factor: 3.862

6.  The relative quiescence of hematopoietic stem cells in nonhuman primates.

Authors:  N Mahmud; S M Devine; K P Weller; S Parmar; C Sturgeon; M C Nelson; T Hewett; R Hoffman
Journal:  Blood       Date:  2001-05-15       Impact factor: 22.113

7.  Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.

Authors:  Steven M Devine; Ron Hoffman; Amit Verma; Rajul Shah; Basil A Bradlow; Wendy Stock; Vera Maynard; Ellen Jessop; David Peace; Marianne Huml; Deana Thomason; Yi-Hsiang Chen; Koen van Besien
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

8.  BclxL overexpression in megakaryocytes leads to impaired platelet fragmentation.

Authors:  Yulia Kaluzhny; Guangyao Yu; Shishinn Sun; Paul A Toselli; Bernhard Nieswandt; Carl W Jackson; Katya Ravid
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

9.  Platelet formation is the consequence of caspase activation within megakaryocytes.

Authors:  Stephane De Botton; Siham Sabri; Eric Daugas; Yael Zermati; Jacques Emmanuel Guidotti; Olivier Hermine; Guido Kroemer; William Vainchenker; Najet Debili
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

10.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

Authors:  L H Boise; M González-García; C E Postema; L Ding; T Lindsten; L A Turka; X Mao; G Nuñez; C B Thompson
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

View more
  88 in total

1.  Efficacy of ALK5 inhibition in myelofibrosis.

Authors:  Lanzhu Yue; Matthias Bartenstein; Wanke Zhao; Wanting Tina Ho; Ying Han; Cem Murdun; Adam W Mailloux; Ling Zhang; Xuefeng Wang; Anjali Budhathoki; Kith Pradhan; Franck Rapaport; Huaquan Wang; Zonghong Shao; Xiubao Ren; Ulrich Steidl; Ross L Levine; Zhizhuang Joe Zhao; Amit Verma; Pearlie K Epling-Burnette
Journal:  JCI Insight       Date:  2017-04-06

Review 2.  JAK2 inhibitors: what's the true therapeutic potential?

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Blood Rev       Date:  2010-11-20       Impact factor: 8.250

Review 3.  GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy.

Authors:  Te Ling; John D Crispino; Maria Zingariello; Fabrizio Martelli; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2018-02-19       Impact factor: 2.929

Review 4.  Leveraging JAK-STAT regulation in myelofibrosis to improve outcomes with allogeneic hematopoietic stem-cell transplant.

Authors:  Michael Byrne; Bipin Savani; Michael R Savona
Journal:  Ther Adv Hematol       Date:  2018-07-16

5.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

6.  Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents.

Authors:  Xiaoli Wang; Wei Zhang; Takefumi Ishii; Selcuk Sozer; Jiapeng Wang; Mingjiang Xu; Ronald Hoffman
Journal:  Cancer Res       Date:  2009-09-14       Impact factor: 12.701

7.  Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Authors:  Christophe Desterke; Christophe Martinaud; Bernadette Guerton; Lisa Pieri; Costanza Bogani; Denis Clay; Frederic Torossian; Jean-Jacques Lataillade; Hans C Hasselbach; Heinz Gisslinger; Jean-Loup Demory; Brigitte Dupriez; Claude Boucheix; Eric Rubinstein; Sophie Amsellem; Alessandro M Vannucchi; Marie-Caroline Le Bousse-Kerdilès
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

8.  Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients.

Authors:  E Masselli; C Carubbi; G Gobbi; P Mirandola; D Galli; S Martini; S Bonomini; M Crugnola; L Craviotto; F Aversa; M Vitale
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

9.  Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation.

Authors:  Stefan O Ciurea; Marcos de Lima; Sergio Giralt; Rima Saliba; Carlos Bueso-Ramos; Borje S Andersson; Chitra M Hosing; Srdan Verstovsek; Richard E Champlin; Uday Popat
Journal:  Biol Blood Marrow Transplant       Date:  2010-01-29       Impact factor: 5.742

10.  Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease.

Authors:  Anna Rita Migliaccio; Fabrizio Martelli; Maria Verrucci; Giovanni Migliaccio; Alessandro Maria Vannucchi; Hongyu Ni; Mingjiang Xu; Yi Jiang; Betty Nakamoto; Thalia Papayannopoulou; Ronald Hoffman
Journal:  Exp Hematol       Date:  2008-02       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.